Breast cancer − medical oncology summary 2021

Česká verzia

Authors: P. Tesařová
Authors place of work: Onkologická klinika Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy, Praha
Published in the journal: Rozhl. Chir., 2021, roč. 100, č. 4, s. 157-165.
Category: Review
doi: https://doi.org/10.33699/PIS.2021.100.4.

Summary

Today, breast cancer has actually become merely an umbrella term that encompasses several cancers with different types of genesis, different genomic and phenotypic characteristics, different needs for systemic treatment and different prognosis. Early diagnosis and good multidisciplinary cooperation, choice of a proper treatment sequence, good supportive treatment and psychological support of the patient are crucial for a therapeutic success.

The surgeon plays an important role in the treatment plan of patients with breast cancer; nevertheless, breast cancer is a systemic disease and thus as a rule, surgery alone is usually not sufficient to manage even early stages of the tumor. Surgeons as members of a multidisciplinary team need to know basic information on systemic treatment of breast cancer and have an understanding of how oncologists think; only then it will possible to achieve multidisciplinary consensus as painlessly as possible in each individual case.

Keywords:

breast cancer − oncological systemic therapy – staging − early breast cancer − metastatic breast cancer

Zdroje

https://ec.europa.eu/jrc/en/news/2020-cancer-incidence-and-mortality-eu-27-countries.
https://www.svod.cz/analyse.php?modul=incmor#.
Escala-Garcia M, Morra A, Canisius S, et al. Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. BMC Med. 2020;18(1):327. doi: 10.1186/s12916-020-01797-2. PMID: 33198768; PMCID: PMC7670589.
https://www.mamo.cz/.
https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. WHO classification of tumours. Vol. 4, 4^th edition. Geneva, IARC Press 2012.
Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67(4):290–303. doi: 10.3322/caac.21393.
Jackson HW, Fischer JR, Zanotelli VRT, et al. The single-cell pathology landscape of breast cancer. Nature 2020 Feb;578(7796):615−620. doi: 10.1038/s41586-019-1876-x.
Tsang JYS, Tse GM. FRCPC molecular classification of breast cancer. Adv Anat Pathol. 2020;27(1):27−35 doi: 10.1097/PAP.0000000000000232.
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206–2223. doi: 10.1093/annonc/mdt303.
Balkenhol MC, Ciompi F, Świderska-Chadaj Ż, et al. Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics. Breast 2021 Feb 17;56:78−87 doi: 10.1016/j.breast.2021.02.007.
Berliner JL, Cummings SA, Boldt Burnett B, et al. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes − practice resource of the National Society of Genetic Counselors. J Genet Couns. 2021; Jan 7. doi: 10.1002/jgc4.1374. Epub ahead of print.
Ibraheem A, Olopade OI, Huo D. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer 2020 Sep 1;126(17):4013-4022. doi: 10.1002/cncr.32956. Epub 2020 Jun 10.
Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): A review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018 Oct;268(4):591−601. doi: 10.1097/SLA.0000000000002953.
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical practice guidelines. Ann Oncol. 2019Aug 1;30(8):1194−1220. doi: 10.1093/annonc/mdz173. Erratum in: Ann Oncol. 2019 Oct 1;30(10):1674.
Zeidman M, Schmidt H, Alberty-Oller JJ, et al. Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB). Breast Cancer Res Treat. 2021 Jan 4. doi: 10.1007/s10549-020-06041-2. Epub ahead of print.
Chalasani P. What are the NCCN guidelines for radical mastectomy in the treatment of breast cancer? Available from: www.medscape.com/answers/1947145-155407/what-are-the-nccn-guidelines-for-radical-mastectomy-in-the-treatment-of-breast-cancer.
Barrio AV, Morrow M. Appropriate margin for lumpectomy excision of invasive breast cancer. Chin Clin Oncol. 2016 Jun;5(3):35. doi: 10.21037/cco.2016.03.22. Epub 2016 Apr 7.
Williamson L. More women dismissing breast reconstruction after mastectomy. Lancet Oncol. 2021 Feb;22(2):e43. doi: 10.1016/S1470-2045(21)00030-9. Epub 2021 Jan 21.
Dixon JM, Cartlidge CWJ. Twenty‐five years of change in the management of the axilla in breast cancer. Breast J. 2020; Jan;26(1):22−26. doi: 10.1111/tbj.13720. Epub 2019 Dec 19.
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310. doi: 10.1016/S1470-2045(14)70460-7.
Khan SA, Zhao F, Solin LJ, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). ASCO 20 Virtual Scientific Program. Abstract LBA2. Presented May 31, 2020.
Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial. Lancet Oncol. 2015 Oct;16(13):1380−1388. doi: 10.1016/S1470-2045(15)00135-7.
Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307−316. doi: 10.1056/NEJMoa1415340.
Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266−273. doi: 10.1016/S1470-2045(14)71221-5.
Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382−2387. doi: 10.1200/JCO.2012.45.2615.
Gera R, Chehade HELH, Wazir U, et al. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis. Sci Rep Feb. 2020;10(1). doi: 10.1038/s41598-020-59908-1.
Burstein HJ, Curigliano G, Loibl S, et al. Members of the St. Gallen International Consensus Panel on the primary therapy of early breast cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541−1557. doi: 10.1093/annonc/mdz235.
Ruhstaller T, Giobbie-Hurder A, Colleoni M, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 2019;37(2):105−114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26.
Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846. doi: 10.1056/NEJMoa1701830.
Lambertini M, Blondeaux E, Perrone F, et al. Improving adjuvant endocrine treatment tailoring in premenopausal women with hormone receptor-positive breast cancer. J Clin Oncol. 2020;38(12):1258−1267. doi: 10.1200/JCO.19.02242. Epub 2019 Oct 16.
Twelves C, Cheeseman S, Sopwith W, et al. Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre. BMC Cancer 2020;20(1):53. doi: 10.1186/s12885-020-6527-y.
Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379(9814):432−444. doi: 10.1016/S0140-6736(11)61625-5. Epub 2011 Dec 5.
Ma SJ, Oladeru OT, Singh AK. Association of adjuvant chemotherapy with overall survival in patients with early-stage breast cancer and 21-gene recurrence scores of 26 or higher. JAMA Netw Open 2020;27(1):27−34. doi: 10.1111/tbj.14130. Epub 2020 Dec 3.
Early Breast Cancer Trialists’ Collaborative Group. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019;393(10179):1440−1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8.
Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147−2159. doi: 10.1056/NEJMoa1612645.
Dent R, Rugo HS. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. Lancet Oncol. 2021;22(1):27−28. doi: 10.1016/S1470-2045(20)30747-6.
Franzoi MA, Romano E, Piccart M. Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol. 2021;32(3):323−336. doi: 10.1016/j.annonc.2020.11.022. Epub 2020 Dec 9.
Denduluri N, Somerfield MR, Chavez-MacGregor M, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(6):685−693. doi: 10.1200/JCO.20.02510. Epub 2020 Oct 20.
Martin M, Holmes FA, Ejlertsen B, et al. ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688−1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.
von Minckwitz G, Huang CS, Mano MS, et al. KATHERINE investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617−628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer. Semin Oncol. 2020;47(5):259−269. doi: 10.1053/j.seminoncol.2020.07.008. Epub 2020 Aug 18.
Waks AG, Winer EP. Breast cancer treatment: A review. JAMA 2019;321(3):288−300. doi: 10.1001/jama.2018.19323.
Early Breast Cancer Trialists’ Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015;386(10001):1353−1361. doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Erratum in: Lancet. 2016 Jan 2;387(10013):30. Erratum in: Lancet. 2017 Jun 24;389(10088):2472.
McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709−715. doi: 10.1200/JCO.2014.57.9029. Epub 2015 Jan 20. Erratum in: J Clin Oncol. 2015 Sep 10;33(26):2934.
Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994−2001. doi: 10.1200/JCO.2018.78.1914. Epub 2018 Apr 5.